Theratechnologies
Market Cap
CA$231.8m
Last Updated
2020/09/25 06:08 UTC
Data Sources
Company Financials +
Executive Summary
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Share Price & News
How has Theratechnologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TH's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-13.8%
TH
-4.4%
CA Biotechs
-3.3%
CA Market
1 Year Return
-45.6%
TH
72.8%
CA Biotechs
-9.7%
CA Market
Return vs Industry: TH underperformed the Canadian Biotechs industry which returned 72.8% over the past year.
Return vs Market: TH underperformed the Canadian Market which returned -9.7% over the past year.
Shareholder returns
| TH | Industry | Market | |
|---|---|---|---|
| 7 Day | -13.8% | -4.4% | -3.3% |
| 30 Day | -11.2% | 12.9% | -4.4% |
| 90 Day | 4.9% | 3.5% | 5.1% |
| 1 Year | -45.6%-45.6% | 72.8%72.8% | -6.5%-9.7% |
| 3 Year | -59.9%-59.9% | 40.5%40.5% | 5.3%-4.9% |
| 5 Year | 44.0%44.0% | -8.4%-8.4% | 38.7%17.3% |
Price Volatility Vs. Market
How volatile is Theratechnologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Type Of Returns Would Theratechnologies'(TSE:TH) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?1 month ago | Simply Wall St
Theratechnologies Inc. (TSE:TH) Is Expected To Breakeven2 months ago | Simply Wall St
Would Theratechnologies (TSE:TH) Be Better Off With Less Debt?Valuation
Is Theratechnologies undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TH (CA$3.01) is trading below our estimate of fair value (CA$18.26)
Significantly Below Fair Value: TH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TH is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: TH is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TH is overvalued based on its PB Ratio (11.2x) compared to the CA Biotechs industry average (6.1x).
Next Steps
Future Growth
How is Theratechnologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
65.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: TH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TH's is expected to become profitable in the next 3 years.
Revenue vs Market: TH's revenue (22.1% per year) is forecast to grow faster than the Canadian market (5.5% per year).
High Growth Revenue: TH's revenue (22.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TH's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Theratechnologies performed over the past 5 years?
-38.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TH is currently unprofitable.
Growing Profit Margin: TH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TH is unprofitable, and losses have increased over the past 5 years at a rate of 38.6% per year.
Accelerating Growth: Unable to compare TH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: TH has a negative Return on Equity (-119.6%), as it is currently unprofitable.
Next Steps
Financial Health
How is Theratechnologies's financial position?
Financial Position Analysis
Short Term Liabilities: TH's short term assets ($72.2M) exceed its short term liabilities ($37.5M).
Long Term Liabilities: TH's short term assets ($72.2M) exceed its long term liabilities ($58.8M).
Debt to Equity History and Analysis
Debt Level: TH's debt to equity ratio (334.3%) is considered high.
Reducing Debt: Insufficient data to determine if TH's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TH has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Theratechnologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TH's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Paul Lévesque (56 yo)
0.42
Tenure
Mr. Paul Lévesque has been President, Chief Executive Officer and Director at Theratechnologies Inc. since April 6, 2020. Mr. Lévesque boasts over 30 years of experience in the pharmaceutical field. After ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP & CFO | 4.58yrs | US$608.25k | 0.036% $ 84.3k | |
| Senior VP & Chief Medical Officer | 4.17yrs | US$949.25k | 0.077% $ 178.5k | |
| Senior VP & Chief Commercial Officer | 1.75yrs | US$656.20k | 0.0065% $ 15.0k | |
| General Manager of Theratechnologies Europe Limited | 1.5yrs | US$810.94k | no data | |
| President | 0.42yr | no data | 0.025% $ 57.8k | |
| VP of Legal Affairs & Corporate Secretary | no data | US$444.16k | 0.023% $ 54.2k | |
| Vice President of Communications & Corporate Affairs | 2.67yrs | US$457.30k | 0.0078% $ 18.0k |
2.2yrs
Average Tenure
53yo
Average Age
Experienced Management: TH's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 0.42yr | no data | 0.025% $ 57.8k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.92yrs | US$106.33k | 0.014% $ 33.4k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 23.67yrs | US$120.00k | 0.51% $ 1.2m | |
| Independent Director | 14.58yrs | US$118.00k | 0.13% $ 301.0k | |
| Independent Chair of the Board | 7.33yrs | US$213.00k | 0.36% $ 823.5k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.33yrs | US$97.50k | 0.022% $ 50.3k |
5.3yrs
Average Tenure
66yo
Average Age
Experienced Board: TH's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Theratechnologies Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Theratechnologies Inc.
- Ticker: TH
- Exchange: TSX
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$231.810m
- Shares outstanding: 77.01m
- Website: https://www.theratech.com
Number of Employees
Location
- Theratechnologies Inc.
- 2015 Peel Street
- 11th Floor
- Montreal
- Quebec
- H3A 1T8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TH | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Dec 1993 |
| TQ8 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 1993 |
| THTX | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Dec 1993 |
Biography
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in h ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/25 06:08 |
| End of Day Share Price | 2020/09/24 00:00 |
| Earnings | 2020/05/31 |
| Annual Earnings | 2019/11/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.